Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas

12 Feb 2020

Abstract excerpt

A subset of gliomas has DNA repair defects that lead to hypermutated genomes. While such tumors are resistant to alkylating chemotherapies, they may also express more mutant neoantigens on their cell surfaces, and thus be more responsive to immunotherapies. A fast, inexpensive method of screening for hypermutated gliomas would therefore be of great clinical value. Since immunohistochemistry (IHC) for the DNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Genetic factors in colorectal cancer
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32051040
DOI: 10.1186/s40478-020-0892-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomasPMID 32051040Read ↗

The efficacy of DNA MMR enzyme immunohistochemistry as a screening test for hypermutated gliomasSemantic proximity Read ↗

Mismatch-Repair Protein Expression in High-Grade Gliomas: A Large Retrospective Multicenter StudySemantic proximity Read ↗

Hypermutation as a Potential Predictive Biomarker of Immunotherapy Efficacy in High-Grade Gliomas: A Broken Dream?Semantic proximity Read ↗

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.Semantic proximity Read ↗

The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas.Semantic proximity Read ↗

Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutationsSemantic proximity Read ↗

MSH2, MSH6, MLH1, and PMS2 immunohistochemistry as highly sensitive screening method for DNA mismatch repair deficiency syndromes in pediatric high-grade gliomaSemantic proximity Read ↗

Mechanisms and therapeutic implications of hypermutation in gliomas.Semantic proximity Read ↗

A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.Semantic proximity Read ↗

The role of MGMT testing in clinical practice: a report of the association for molecular pathology.Semantic proximity Read ↗

The efficacy of immunohistochemistry in the diagnosis of molecular genetic alterations in central nervous system gliomas: Next-generation sequencing of 212 mutations in 112 patients.Semantic proximity Read ↗

Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse GliomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.